Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Kisspeptin-10
Also known as: KP-10, Metastin 45-54, Kisspeptin
Kisspeptin-10 is the shortest bioactive fragment of the kisspeptin neuropeptide family, acting upstream of GnRH to stimulate the entire reproductive hormone cascade. It is being investigated as a physiological tool for diagnosing and treating reproductive disorders, representing a novel approach to HPT axis stimulation.
Risk Level
Low RiskDifficulty
Advanced| CAS Number | 374675-21-5 |
| Molecular Formula | C63H83N17O14 |
| Class | Peptide |
| Category | SERMs & AIs |
Mechanism of Action
Kisspeptin-10 binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus, triggering GnRH release in a pulsatile pattern. This represents the most upstream pharmacological intervention point in the HPT axis. It produces robust, dose-dependent increases in LH, FSH, and subsequently testosterone. Tachyphylaxis (receptor desensitization) can occur with continuous exposure, suggesting intermittent dosing is preferred.
Dosing Research
Clinical research: 0.01-1.0 nmol/kg IV or SC. Research community protocols: 100-500 mcg SC 1-2 times daily. Very short half-life of approximately 4-6 minutes for the KP-10 fragment. No established clinical dosing protocols for hypogonadism yet. Longer kisspeptin analogs are in development for improved pharmacokinetics.
Side Effects & Risks
Minimal side effects reported in clinical trials. Transient facial flushing and warmth at higher doses. No serious adverse events documented. Long-term safety data is lacking. Tachyphylaxis may limit efficacy with chronic continuous use. Considered investigational with limited human data outside of controlled studies.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.